Beta-asarone
Based on 4 publication(s) in Google Scholar
Beta-asarone is an orally active and BBB-penetrable anti-inflammatory agent and neuroprotective agent, which is the major ingredient of Acorus tatarinowii Schott. Beta-asarone can protect nerve cells from apoptosis and autophagy, inhibit expression of α-synuclein, as well as myocardial protection. Beta-asarone can be used in the study of neurological and cardiovascular diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.94%
- CAS No.: 5273-86-9
- Formule: C12H16O3
- Masse moléculaire:208.25
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Neuronal Signaling Compound Library
HY-L013
-
Natural Product Library
HY-L021
-
CNS-Penetrant Compound Library
HY-L028
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Medicine Food Homology Compound Library
HY-L055
-
Orally Active Compound Library
HY-L061
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neuroprotective Compound Library
HY-L070
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
PBCRBS Traditional Chinese Medicine Compound Library
HY-L193
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library
HY-L223
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Beta-asarone
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
Voir tous les produits spécifiques à Isoform α-synuclein
More
Activité biologique
|
α-synuclein |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
126.11 μM
Compound: A, beta-Asarone
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 23395966] |
| MCF7 | IC50 |
129.35 μM
Compound: A, beta-Asarone
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 23395966] |
| Oocyte | EC50 |
171.5 μM
Compound: 1
|
Allosteric modulation of rat gamma-aminobutyric acid receptor A alpha1beta2gamma2S expressed in Xenopus oocytes assessed as potentiation of GABA-mediated chloride current after 20 secs by voltage clamp assay
Allosteric modulation of rat gamma-aminobutyric acid receptor A alpha1beta2gamma2S expressed in Xenopus oocytes assessed as potentiation of GABA-mediated chloride current after 20 secs by voltage clamp assay
|
[PMID: 21563811] |
| SW982 | IC50 |
>150 μM
Compound: A, beta-Asarone
|
Cytotoxicity against human SW982 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human SW982 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 23395966] |
Beta-asarone (7.5-30 μg/mL; 25 h) can protect PC12 cells against Aβ1-42 induced cytotoxicity and autophagy[1].
Beta-asarone (100 μM; 2 h) inhibits the up-regulation of MALAT1 and α-synuclein expression in SH-SY5Y cells treated with MPP+ (HY-W008719)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MPP+ (HY-W008719) treated SH-SY5Y cells
-
Concentration:100 μM
-
Incubation Time:2 h
-
Result:Down-regulated the mRNA levels of MALAT1 and α-synuclein.
Beta-asarone (oral administration; 12.5-50 mg/kg; 28 days) alleviates Aβ1–42-induced apoptosis of hippocampal neurons in a rat model of Alzheimer's disease[3].
Beta-asarone (intraperitoneal injection; 10-30 mg/kg; single dose) has anti-inflammatory and protective effects in a rat model of myocardial ischemia-reperfusion[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MPTP (HY-15608) treated male C57BL/6 mice aged 9-10 weeks old[2]
-
Dosage:10 mg/kg
-
Administration:Intragastric administration; 28 days
-
Result:Markedly increased the TH+ cells of MPTP induced PD mouse.
Down-regulated the expression levels of MALAT1 and α-synuclein in midbrain.
Increased the expression levels of Bcl-2.
-
Animal Model:Ischemic-reperfusion treated male Sprague-Dawley rats (240-280g)[4]
-
Dosage:10, 20 and 30 mg/kg
-
Administration:Intraperitoneal injection (i.p.); single dose
-
Result:Significantly improved the heart outcome after myocardial ischemia and reperfusion in terms of less infarction size and lower serum cTNT concentration.
Evidently inhibited inflammatory response with less granulocyte infiltration, mild tissue edema and lower tissue MPO content.
Suppressed NLRP3 signal pathway and cardiac cell’s pyroptosis for less protein expressions of ASC and NLRP3, lower level cleavage activation of caspase-1and GSDMSD, and lower serum IL-1β concentration.
Well preserved the left ventricular performance with higher ejection fraction and fractional shortening.
Chemical Information
-
CAS No. 5273-86-9
-
Appearance Liquid (Density: 1.073 g/cm3)
-
Masse moléculaire 208.25
-
Formule C12H16O3
-
Color Colorless to light yellow
-
SMILES
C/C=C\C1=C(OC)C=C(OC)C(OC)=C1
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Eur J Pharmacol
Beta-asarone alleviated cerebral ischemia/reperfusion injury by targeting PINK1/Parkin-dependent mitophagy. [Abstract]2025 Sep 5:1002:177831. PMID: 40490171 -
Cancer Med
β-asarone inhibits the migration, invasion, and EMT of bladder cancer through activating ER stress. [Abstract]2023 Jun;12(12):13610-13622. PMID: 37306628 -
Biochem Genet
β-Asarone Inhibits Carboplatin Resistance in Retinoblastoma Cells Through the UCA1/miR-206/NRP1 Axis. [Abstract]2024 Dec 24. PMID: 39718722 -
Int Ophthalmol
β-asarone attenuates the proliferation, migration and enhances apoptosis of retinoblastoma through Wnt/β-catenin signaling pathway. [Abstract]2023 May;43(5):1687-1699. PMID: 36372820
Beta-asarone purchased from MedChemExpress. Usage Cited in: Int Ophthalmol. 2023 May;43(5):1687-1699. [Abstract]
Beta-asarone (β-asarone; 100 μM; 24 h) signifcantly reduces the proliferation of RB cells.
Beta-asarone purchased from MedChemExpress. Usage Cited in: Int Ophthalmol. 2023 May;43(5):1687-1699. [Abstract]
Beta-asarone (β-asarone; 100 μM; 4 h) facilitates the apoptosis of RB cells.
Solvant et solubilité
DMSO : 100 mg/mL (480.19 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.75 mg/mL (13.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.75 mg/mL (13.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (282 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Xue Z, et al. Beta-asarone attenuates amyloid beta-induced autophagy via Akt/mTOR pathway in PC12 cells. Eur J Pharmacol. 2014 Oct 15;741:195-204. [Content Brief]
[2]. Zhang QS, et al. Beta-asarone protects against MPTP-induced Parkinson's disease via regulating long non-coding RNA MALAT1 and inhibiting α-synuclein protein expression. Biomed Pharmacother. 2016 Oct;83:153-159. [Content Brief]
[3]. Liu J, et al. Beta-asarone attenuates neuronal apoptosis induced by Beta amyloid in rat hippocampus. Yakugaku Zasshi. 2010 May;130(5):737-46. [Content Brief]
[4]. Xiao B, et al. Beta-Asarone Alleviates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammatory Response and NLRP3 Inflammasome Mediated Pyroptosis. Biol Pharm Bull. 2020 Jul 1;43(7):1046-1051. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.8019 mL | 24.0096 mL | 48.0192 mL | 120.0480 mL |
| 5 mM | 0.9604 mL | 4.8019 mL | 9.6038 mL | 24.0096 mL | |
| 10 mM | 0.4802 mL | 2.4010 mL | 4.8019 mL | 12.0048 mL | |
| 15 mM | 0.3201 mL | 1.6006 mL | 3.2013 mL | 8.0032 mL | |
| 20 mM | 0.2401 mL | 1.2005 mL | 2.4010 mL | 6.0024 mL | |
| 25 mM | 0.1921 mL | 0.9604 mL | 1.9208 mL | 4.8019 mL | |
| 30 mM | 0.1601 mL | 0.8003 mL | 1.6006 mL | 4.0016 mL | |
| 40 mM | 0.1200 mL | 0.6002 mL | 1.2005 mL | 3.0012 mL | |
| 50 mM | 0.0960 mL | 0.4802 mL | 0.9604 mL | 2.4010 mL | |
| 60 mM | 0.0800 mL | 0.4002 mL | 0.8003 mL | 2.0008 mL | |
| 80 mM | 0.0600 mL | 0.3001 mL | 0.6002 mL | 1.5006 mL | |
| 100 mM | 0.0480 mL | 0.2401 mL | 0.4802 mL | 1.2005 mL |
Beta-asarone Related Classifications
HY-N1501 Related Classifications
Powered by Bioz